Wockhardt has set its eyes on biotechnology companies in China and the US. It has been in talks with four research-based biotechnology companies in China and three bio-pharma companies in the US for the purpose, sources close to the development said.
Two leading consultants including Frost & Sullivan have been appointed by the company to conduct due diligence on the proposed acquisitions. Wockhardt executives declined to comment on the development.